Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and supporting patients, their caregivers and healthcare professionals to complete Advance Care Panning documentation.
The GWG helps people clarify and identify their priorities, should they be affected by a chronic, disabling and potentially non-healing illness. In fact, the GWG consists of a small deck of cards, and on each card is a concrete action or situation that may be important to a person at the end of life.
The "Onco-hema Go wish-ACP" project aims to evaluate the feasibility of a Go Wish Game-based intervention with patients with refractory lymphoma, leukemia or multiple myeloma or advanced solid tumors with prognosis > 3 months.
In terms of secondary objectives, the study aims to.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients affected by refractory lymphomas, or leukemia or myeloma multiple or advanced solid tumors | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Go Wish Game | Other | The Go Wish Game (GWG) provides a simple tool, composed by 35 cards to identify individual priorities. GWG is welcomed as a first step in clarifying values and personal thoughts linked to the end of life. The GWG discussion will be divided into two meetings. During the first one, the physician instructs the patients and their caregivers on how the GWG works. The patient will be invited to divide the cards into three sets, labeling the content of the cards within each set as: Very important;more or less important and not important. This will be the base for the second meeting. During the second meeting - scheduled within one week - each category of card sets will be discussed with patients and their caregivers. The identification of the most relevant wishes or priorities of each patient will be incorporated into the individual therapeutic plan and the patient will be offered the option to make a formal ACP in the following 4 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Intervention Feasibility | We will evaluate the feasibility of the intervention. Feasibility will be investigated by:
4. proportion of enrolled patients that will complete the ACP document (after participating in all the planned GWG discussions) | 1 Year |
| Measure | Description | Time Frame |
|---|---|---|
| ACP Engagement; | We will further assess and compare the intervention within hemato-oncological and oncological patients in terms of: 1. ACP engagement: we will use the 4-item ACP Engagement (4-item ACP-E) questionnaire | 18 Months |
| Quality of Communication; |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marta Perin (Dr), PhD | Contact | +39 3463576133 | marta.perin@ausl.re.it | |
| Andrea Fusco, MSc | Contact | +39 3409136595 | andrea.fusco@ausl.re.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AziendaUSL IRCCS Reggio Emilia | Recruiting | Reggio Emilia | Italy |
We share individual information about gender, age, work occupation, disease type, prognosis and time of diagnosis.
Not provided
The access will be able only to those people in terms of clinical staff, who are involved in the study
Not provided
Not provided
| ID | Term |
|---|---|
| D007938 | Leukemia |
| D008223 | Lymphoma |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
We will further assess and compare the intervention within hemato-oncological and oncological patients in terms of: 2. Quality of communication: we will use the 19-item Quality of Communication (QOC) questionnaire |
| 18 Months |
| Meaning of Life; | We will further assess and compare the intervention within hemato-oncological and oncological patients in terms of: 3. Meaning of life: we will use the Meaning in Life scale (MLS) | 18 Months |
| Impact on patients' hope | We will further assess and compare the intervention within hemato-oncological and oncological patients in terms of: 4. Impact on patients' hope: we will use the Hope Herth Index (HHI) | 18 Months |
| Acceptability | 5. Acceptability of intervention in terms of recruitment and intervention delivery will be further investigated by: semi-structured interviews with patients and caregivers and FG with HPs who applied the GWG. . | 18 Months |
| ACP documentation | We will analyze the ACP documentation of patients enrolled to qualitatively investigate the congruence and relations between the priorities defined during the GWG meetings and the decisions written in the care plan | 18 Months |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |